Records containing: Primary Open-Angle Glaucoma

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2024-11-18
  Pilot Study to Evaluate Clinically the Short-Term Efficacy of GlaucoT Glaucoma Treatment Glasses in the Treatment of Primary Open-Angle Glaucoma (GlaucoT)
• CLINICAL_TRIALS study record update · 2022-12-22
  ClinicalTrials.gov study NCT02327312
• CLINICAL_TRIALS study record update · 2021-04-30
  A 2-STAGE, PHASE 2, DOUBLE-MASKED, RANDOMIZED, VEHICLE CONTROLLED, DOSE RESPONSE TRIAL OF PF-04217329 AND THE MARKETED FORMULATION OF LATANOPROST IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
• CLINICAL_TRIALS study record update · 2020-06-04
  A Phase 2 Prospective, Multicenter, Randomized, Double-masked, Controlled Study to Evaluate the Efficacy and Safety and Dose-response of the Bimatoprost Ocular Insert (2.2 mg, 13 mg) With and Without Concomitant Artificial Tears Compared to a Placebo Ocular Insert With and Without Concomitant Timolol (0.5%) Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
• CLINICAL_TRIALS study record update · 2019-02-26
  An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2019-02-26
  An Open-Label Extension (OLE) Study to Evaluate the Safety of the ForSight VISION5 Product in Subjects With Open-Angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-002
• CLINICAL_TRIALS study record update · 2018-04-20
  A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
• CLINICAL_TRIALS study record update · 2017-07-21
  Effectiveness and Safety of Subtenon Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration
• CLINICAL_TRIALS study record update · 2014-11-17
  Effect of Selective Laser Trabeculoplasty on the Intraocular Pressure Nycthemeral Rhythm.
• CLINICAL_TRIALS study record update · 2014-08-05
  ClinicalTrials.gov study NCT01110499